ePT--the Electronic Newsletter of Pharmaceutical Technology, Mar 10, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Mar 10, 2011
News
Japan Halts Use of Pfizer and sanofi Vaccines
By Stephanie Sutton
Japan has suspended the use of two pediatric vaccines made by Pfizer and sanofi following the deaths of four children in three days.
Regulatory Roundup: FDA Posts PDUFA Meeting Minutes
FDA Posts PDUFA Meeting Minutes
Hamburg Describes Efforts to Develop Medical Countermeasures
By Erik Greb
At a conference on preserving national security at the University of Pittsburgh Medical Center last week, FDA Commissioner Margaret Hamburg stressed the importance of medical countermeasures for responding to natural and deliberate threats to public health.
AstraZeneca Discontinues Pulmicort Production
By Patricia Van Arnum
AstraZeneca announced this week that it will discontinue the production of Pulmicort (budesonide) 100 and 200 µg/dose HFA (hydrofluoroalkane) pressurized metered-dose inhaler (pMDI) due to manufacturing issues related to technical aspects of the device, which prevents the ongoing manufacture of the product.
Week of Mar. 7, 2011: Company and People Notes: WuXi and BMS Form Collaboration; F. Michael Ball Leaves Allergan for Hospira; and More.
WuXi and BMS Form Collaboration; F. Michael Ball Leaves Allergan for Hospira; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here